HR Execs on the Move

Elligo Health Research

www.elligohealthresearch.com

 
Elligo Health Research helps speed new therapies to market by providing large numbers of patients and clinicians the opportunity to participate in clinical research. Elligo enables rapid and effective clinical trial enrollment and facilitates the study site operations so that clinicians can focus on their research. Our unique direct to patient model allows us to streamline patient identification and qualification, site activation, patient enrollment, study initiation and study conclusion for more efficient and cost-effective trials.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Alyssa Kelliher Kent
 Executive Director Marketing Communications Profile
Joseph Amador
 Executive Director, Talent Acquisition Profile
John Potthoff
 Chief Executive Officer Profile
Andy Johnson
 Director of Learning and Development Profile

Similar Companies

BioScrip

BioScrip is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stago

DrugSense

DrugSense is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Certified Safety

TransCode Therapeutics

TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.